Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 25, 2008 Brian Orelli	Generic Heartburn at Wyeth Revenue from its heartburn drug Protonix dropped 59% year over year after Teva Pharmaceuticals and Sun Pharmaceuticals launched their generic versions of the drug.
The Motley Fool January 23, 2009 Brian Orelli	Wyeth Isn't Cheap Enough for Pfizer The Wall Street Journal reports that Pfizer is in talks to acquire Wyeth for $60 billion or more. Should they do it?
The Motley Fool April 29, 2009 Brian Orelli	The Other 33.1% of Pfizer Reports The take-home message for current and future Pfizer shareholders from Wyeth's quarterly report is that they're not getting a growth monster, but Wyeth's revenue is fairly stable.
The Motley Fool March 28, 2008 Brian Orelli	Wyeth Fires to Get Back on Fire The first round of Wyeth's cuts look like the right move for the big pharma company.
The Motley Fool July 24, 2009 Brian Orelli	Pfizer's Bride Puts on the Makeup Pfizer may not be getting a powerhouse revenue driver in Wyeth, but at least its bride knows how to make the bottom line look pretty.
The Motley Fool August 3, 2007 Billy Fisher	Stormy Waters at Wyeth The downward trend in the price of Wyeth shares may have painted a grim picture for the stock's future; however, the company has already demonstrated its ability to grow revenues despite the competition from generics.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool December 26, 2007 Brian Orelli	Teva's Heartburning Battle Teva launches its generic version of Wyeth's and Altana's heartburn medication, Protonix; those companies attempt to get a preliminary injunction. There are high stakes on both sides of the dispute.
The Motley Fool April 25, 2008 Brian Orelli	Progenics' Double Dose of Good News Its lead drug gets FDA approval and a positive EU recommendation.
The Motley Fool May 23, 2008 Brian Orelli	Progenics' Mixed Trial Data Progenics Pharmaceuticals and marketing partner Wyeth release both positive and negative clinical trial data.
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool September 24, 2009 Brian Orelli	Wyeth's Biting the Hand That Feeds It Wyeth decides to sue the Food and Drug Administration after it approved Orchid Chemicals & Pharmaceuticals' generic version of its antibiotic Zosyn.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
The Motley Fool May 22, 2008 Brian Orelli	Wyeth's Never-Ending Generic Woes Novartis jumps on the generic Protonix bandwagon.
The Motley Fool March 13, 2008 Brian Orelli	Progenics Down but Not Out Progenics Pharmaceuticals' drug to help patients after abdominal surgery fails in its phase 3 trial. Investors, take note.
The Motley Fool September 15, 2010 Brian Orelli	Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer.
The Motley Fool April 20, 2007 Billy Fisher	Many Ways to Feel Good About Wyeth The drugmaker's pipeline makes investors look forward to the next few quarters, too.
The Motley Fool February 13, 2008 Brian Orelli	Teva Tears It Up After a stellar 2006 because of exclusive launches of some big-time generics, it seemed like Teva Pharmaceuticals would have a heck of a time keeping the pace up in 2007. Apparently, that fear was unwarranted.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool January 30, 2007 Brian Lawler	Wyeth's Slow Growth Wyeth releases its 2006 financial results and guides for another year of slow growth. Investors, take note.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool September 15, 2008 Brian Orelli	Teva and FDA's Never-Ending Court Battle The Food and Drug Administration has won the latest installment of its grudge match with Teva Pharmaceuticals over the 180-day exclusivity period for generic versions of Johnson & Johnson's Risperdal.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool February 17, 2010 Brian Orelli	$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%.
The Motley Fool July 9, 2009 Brian Orelli	Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable.
The Motley Fool September 22, 2008 Brian Orelli	Ouch, That's Gotta Hurt! Acupuncture beats Wyeth's Effexor in stopping hot flashes.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
The Motley Fool July 27, 2010 Brian Orelli	Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts.
The Motley Fool August 28, 2008 Brian Orelli	Me-Too Drugs: Are They Worth It? These drugs have less risk, but also usually bring less of a reward to the companies that make them.
The Motley Fool June 13, 2008 Brian Orelli	Some Insight Into Incyte's Data Incyte's rheumatoid arthritis drug looks promising, according to early numbers.
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
The Motley Fool July 20, 2007 Billy Fisher	Wyeth Keeps Working Its Magic The drugmaker's second-quarter boasts 12% earnings growth. Of particular promise was the reversal over first-quarter for its top seller, the antidepressant Effexor.
The Motley Fool June 18, 2007 Billy Fisher	Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high.
The Motley Fool October 14, 2009 Brian Orelli	Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out.
The Motley Fool April 21, 2006 Stephen D. Simpson	Wily Wyeth For the most part, this business will produce high-single-digit revenue growth, and hopefully low-teens growth in earnings and cash flow. That means investors should be a little conservative buying in, but patient when holding.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool January 22, 2004 Alyce Lomax	Worries for Wyeth Despite pain-free vaccine, the drug maker's results are still painful.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool October 19, 2007 Billy Fisher	Wyeth's Resilience Wyeth's latest quarter is an outstanding example of the drugmaker's consistency; the company reports solid results from all of its businesses, along with a 9% increase in sales.
The Motley Fool October 19, 2006 Brian Lawler	A Yawn and More Growth From Wyeth Investors, the numbers aren't all that new, but they are good. With its guidance of $3.12 to $3.18 in EPS for the year and a steadily increasing dividend, Wyeth is a good candidate for investors who want to get a start in this sector
The Motley Fool June 27, 2007 Billy Fisher	Improving Morale at Barr Preliminary OK of Barr Pharmaceutical's generic antidepressant perks up the stock's potential.
The Motley Fool December 11, 2009 Brian Orelli	Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
The Motley Fool June 18, 2008 Brian Lawler	Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool December 14, 2007 Brian Orelli	An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note.
The Motley Fool April 27, 2009 Brian Orelli	Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA.